Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:35 AM
Ignite Modification Date: 2025-12-25 @ 12:35 AM
NCT ID: NCT06132867
Eligibility Criteria: Inclusion Criteria: 1. Continuous nonsmoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study. 2. Body mass index (BMI) ≥18.0 and ˂32.0 kilograms per meters squared (kg/m\^2) at screening. 3. Pulse rate between 60 and 100 beats per minute (bpm) and a blood pressure between 90 to 140 millimeters of mercury (mmHg) systolic and 40 to 90 mmHg diastolic at screening and prior to dosing of Period 1. 4. Creatine phosphokinase is ≤1.1x upper limit of normal \[ULN\]; lipase, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, glucose, and activated partial thromboplastin time (aPTT) are ≤ULN at screening and check-in of Period 1. Exclusion Criteria: 1. Any history of major surgery. 2. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds. 3. Unable to refrain from or anticipates the use of any drug, including prescription and nonprescription medications, herbal remedies, or vitamin supplements within 28 days prior to the first dosing and throughout the study. 4. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV). 5. Positive coronavirus disease 2019 (COVID-19) results at first check-in. 6. Donation of blood or significant blood loss within 56 days prior to the first dosing. 7. Plasma donation within 7 days prior to the first dosing.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 55 Years
Study: NCT06132867
Study Brief:
Protocol Section: NCT06132867